INSULIN RESISTANCE IN NONALCOHOLIC FATTY LIVER DISEASE A CASE CONTROL STUDY

非酒精性脂肪肝的胰岛素抵抗病例对照研究

• 批准号: 7374679
• 负责人: MANAL F. ABDELMALEK
• 金额: $ 1.65万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374679
• 关键词: INSULIN; RESISTANCE; NONALCOHOLIC; FATTY; LIVER

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by diffuse fatty infiltration and inflammation in those who do not consume any alcohol 1. The exact prevalence of NAFLD is unknown; however, based on the known prevalence of benign steatosis and steatohepatitis in those with obesity and type 2 diabetes, NAFLD is now estimated to be the third leading cause of chronic liver disease in the United States 2. Given that the prevalence of obesity could reach 40% by the year 2025 3, it is clear NAFLD is a significant current and future public health concern. NAFLD may be an early manifestation of insulin resistance (IR), but it remains unclear whether IR is associated with NAFLD or an extraneous factor present in those patients with NAFLD. IR may purely be associated with obesity and/or reflect the presence of underlying liver disease irrespective of the presence of steatosis. Since insulin is primarily cleared by the liver, discerning whether hyperinsulinemia is secondary to impaired hepatic clearance or overproduction of insulin is important.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。非酒精性脂肪性肝病（NAFLD）是一种肝脏疾病，其特征是弥漫性脂肪浸润和炎症，发生在不饮酒的人群中。NAFLD的确切患病率尚不清楚;然而，基于肥胖和2型糖尿病患者中良性脂肪变性和脂肪性肝炎的已知患病率，NAFLD现在估计是美国慢性肝病的第三大原因2。鉴于肥胖的患病率到2025年可能达到40%，很明显NAFLD是当前和未来的一个重大公共卫生问题。 NAFLD可能是胰岛素抵抗（IR）的早期表现，但IR是否与NAFLD或NAFLD患者中存在的外源性因素相关仍不清楚。IR可能纯粹与肥胖相关和/或反映存在基础肝病，而不考虑是否存在脂肪变性。由于胰岛素主要由肝脏清除，因此辨别高胰岛素血症是否继发于肝脏清除受损或胰岛素产生过多是重要的。